Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals    VRTX

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Vertex Pharmaceuticals Incorporated : VRTX, OSTK, and GRPN added to Nasdaq Gainers Watch List at GSR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/19/2013 | 05:40pm CEST

New York, NY -- (ACCESSWIRE) -- 04/19/2013 -- Growing Stock Report initiates a NASDAQ Gainers Weekly Watch List adding Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Overstock.com Inc. (NASDAQ:OSTK), Groupon, Inc. (NASDAQ:GRPN), BioScrip Inc. (NASDAQ:BIOS) and Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX).

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) a company that engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases is currently up (+55.57%) on 13,455,455 shares traded after announcing statistically significant results from a phase 2 study for the treatment of cystic fibrosis. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is currently up (+134.49%) from its recent 52-week low which has prompted Growing Stock Report to add the stock to their NASDAQ Gainers Watch List.

To see what other Investors are saying about Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=VRTX&SubId=AW

Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) a development-stage specialty pharmaceutical company is currently up (+24.10%) on 1,789,829 shares traded after Coverage was initiated on Catalyst Pharmaceutical by Aegis Capital. Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) is currently up (+105.41%) from its recent 52-week low which has prompted Growing Stock Report to add the stock to their NASDAQ Gainers Watch List.

To see what other Investors are saying about Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=CPRX&SubId=AW

Also mentioned in Growing Stock Report's Nasdaq Gainers Watch List and Investor Poll was: Overstock.com Inc. (NASDAQ:OSTK), Groupon, Inc. (NASDAQ:GRPN), Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) and BioScrip Inc. (NASDAQ:BIOS).

To see what other Investors are saying about: OSTK, GRPN, CPRX and BIOS

Click Here: http://www.growingstockreport.com/PR.aspx?stock=OSTK-GRPN-CPRX-BIOS&SubID=AW

GrowingStockReport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals GrowingStockReport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.GrowingStockReport.com

Disclosure: GrowingStockReport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit GrowingStockReport.com website, for complete risks and disclosures.

Contact Info:
Growing Stock Report
editor@GrowingStockReport.com


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VERTEX PHARMACEUTICALS
08/10 VERTEX PHARMACEUTICALS : FDA Approves KALYDECO® ivacaftor for More Than 600 Peop..
08/07 VERTEX PHARMACEUTICALS : Breakfast Technical Briefing on Biotech Stocks -- Sarep..
08/03 DATA ON GASTROENTEROLOGY REPORTED BY : Impact of Measured,...
08/03 CONCERT PHARMACEUTICALS : Announces Termination of the HSR Act Waiting Period fo..
08/03 VERTEX PHARMACEUTICALS : and Concert Pharmaceuticals Complete Asset Purchase Agr..
08/03 VERTEX PHARMACEUTICALS : Corporate News Blog - Vertex Pharma Announces Approval ..
08/02 VERTEX PHARMACEUTICALS INCORPORATED : - FDA Approves KALYDECO for More Than 600 ..
08/01 VERTEX PHARMACEUTICALS : FDA Approves KALYDECO® (ivacaftor) for More Than 600 Pe..
07/28 VERTEX PHARMACEUTICALS : MA Management's Discussion and Analysis of Financial Co..
07/28 VERTEX PHARMACEUTICALS : Concert Pharma complete asset purchase agreement for CT..
More news
News from SeekingAlpha
08/13 Vertex Pharmaceuticals May Be Turning Some Major Corners
08/09 VALUATION DASHBOARD : Healthcare - Update
08/07 Vanguard Brings You Healthy Returns With Less Volatility
08/02 Studying Momentum In Health Care Stocks In The S&P 500
08/01 Vertex Pharma raises Kalydeco sales guidance after FDA OKs expanded use
Financials ($)
Sales 2017 2 279 M
EBIT 2017 484 M
Net income 2017 184 M
Finance 2017 727 M
Yield 2017 -
P/E ratio 2017 206,70
P/E ratio 2018 88,36
EV / Sales 2017 16,4x
EV / Sales 2018 13,6x
Capitalization 38 163 M
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | VRTX | US92532F1003 | 4-Traders
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 178 $
Spread / Average Target 18%
EPS Revisions
Managers
NameTitle
Jeffrey M. Leiden Chairman, President & Chief Executive Officer
Ian F. Smith EVP, Chief Operating & Financial Officer
Jeffrey A. Chodakewitz Chief Medical Officer & Executive Vice President
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Reshma Kewalramani Senior VP-Clinical Development & Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
VERTEX PHARMACEUTICALS107.30%38 163
AMGEN16.30%125 059
CELGENE CORPORATION13.40%102 691
GILEAD SCIENCES2.43%95 790
REGENERON PHARMACEUTICALS28.73%50 205
ACTELION24.26%30 756